Companies that fail to plan for and address risk management requirements could face delays in making submissions and in getting a regulatory decision on submissions.
Other content in this Stream
Commercial and regulatory strategy considerations for biotech
In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy innovations in the biotech pipeline make it to patients sooner.
4:24Parexel Biotech – a patient-centric approach is in our DNA
Hear firsthand from Monica about her personal journey as a clinical trial participant to understand the value of easing patient burden
2:55Parexel Biotech – designed with biotech’s unique way of working in mind
James Anthony, SVP, Global Head Biotech and Graciela Rácaro, SVP, Global Head, Biotech Operations, both from Parexel, discuss how Parexel Biotech has been built to meet customer and patient needs
Improving Drug Development & Patient Access With the Right People, Processes, and Culture
Learn about Parexel® Biotech
Focused on meeting customer and the patient needs with tailored, flexible solutions that speed up development and increase the likelihood of launch so that we get treatments into the hands of patients
The hidden value of early patient centricity: practical solutions for early phase trials
Learn about five economical and efficient ways to make early phase trials both patient-centric and more effective.
Venturing into a new era of CNS drug development to improve success